A retrospective, cohort study assessing how pneumococcal vaccination affects Streptococcus pneumoniae protection, hospitalization rates, and associated comorbidities in immunodecient individuals
Latest Information Update: 08 Apr 2022
At a glance
- Drugs Pneumococcal 13-valent CRM197 vaccine conjugate (Primary) ; Pneumococcal 23-valent vaccine Walvax Biotechnology (Primary)
- Indications Pneumococcal infections
- Focus Therapeutic Use
- 08 Apr 2022 New trial record
- 28 Feb 2022 Results presented at the 2022 Annual Meeting of the American Academy of Allergy, Asthma and Immunology